Vical Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
31,238.00
16,492.00
9,238.00
8,973.00
12,960.00
16,254
Depreciation, Depletion & Amortization
2,213.00
1,663.00
1,159.00
1,117.00
793.00
151
Other Funds
482.00
59.00
23.00
14.00
4.00
1,501
Funds from Operations
24,677.00
11,335.00
5,173.00
6,492.00
11,411.00
17,604
Changes in Working Capital
5,121.00
1,529.00
1,775.00
1,896.00
2,810.00
3,159
Net Operating Cash Flow
29,798.00
9,806.00
6,948.00
8,388.00
8,601.00
14,445
Capital Expenditures
744.00
354.00
125.00
255.00
80.00
Sale of Fixed Assets & Businesses
49.00
15.00
3.00
-
-
Purchase/Sale of Investments
25,837.00
12,087.00
69.00
7,417.00
5,211.00
Net Investing Cash Flow
25,142.00
12,426.00
53.00
7,672.00
5,291.00
Net Financing Cash Flow
334.00
3,866.00
20.00
7,744.00
30,545.00
Net Change in Cash
4,322.00
18,366.00
7,021.00
8,316.00
16,653.00
Free Cash Flow
30,130.00
9,891.00
7,020.00
8,643.00
8,681.00
Change in Capital Stock
816.00
3,925.00
3.00
7,758.00
30,549.00

About Vical

View Profile
Address
10390 Pacific Center Court
San Diego California 92121
United States
Employees -
Website http://www.vical.com
Updated 07/08/2019
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E.